Emily Phillips, PA
Medical · Rockingham, NCNPI 1992779466
Payments from drug & device makers
Across 281 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$792
- AstraZeneca$598
- AbbVie$558
- Boehringer Ingelheim$457
- Lilly USA, LLC$451
- GSK$243
- plus $1K from 28 others
What the payments were for
- Food & beverage$4,545100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $792 |
| AstraZeneca | 33 | $598 |
| AbbVie | 31 | $558 |
| Boehringer Ingelheim | 27 | $457 |
| Lilly USA, LLC | 32 | $451 |
| GSK | 15 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $177 |
| Pfizer | 9 | $154 |
| Sanofi-aventis U.S. LLC | 8 | $145 |
| Novartis | 7 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $99 |
| Exact Sciences | 6 | $95 |
| Abbott | 4 | $75 |
| Bayer | 4 | $69 |
| Merck | 4 | $64 |
| Shield Therapeutics Inc | 3 | $50 |
| Johnson & Johnson | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $33 |
| Mylan Specialty L.p. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Amgen | 2 | $27 |
| Viatris Specialty LLC | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Corcept Therapeutics | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
| Organon | 1 | $10 |
How this compares
$4,559 in reported general payments places this provider in the 85th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 163 | $133,974 |
| OzempicSemaglutide | 89 | $95,974 |
| MounjaroTirzepatide | 85 | $93,424 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $65,537 |
| JanuviaSitagliptin Phosphate | 80 | $64,216 |
| TrulicityDulaglutide | 53 | $63,289 |
| FarxigaDapagliflozin Propanediol | 58 | $53,602 |
| LinzessLinaclotide | 66 | $47,779 |
| EliquisApixaban | 59 | $46,263 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $40,746 |
| RybelsusSemaglutide | 27 | $33,937 |
| XareltoRivaroxaban | 28 | $30,952 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $20,295 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $18,379 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $11,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy, Spiriva Respimat | $457 | $156,720209 claims |
| Lilly USA, LLCMounjaro, Trulicity | $451 | $156,714138 claims |
| Novo NordiskOzempic, Rybelsus | $792 | $129,911116 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $243 | $96,195156 claims |
| MerckJanuvia | $64 | $64,21680 claims |
| AstraZenecaFarxiga, Symbicort | $598 | $57,32074 claims |
| AbbVieLinzess, Synthroid | $558 | $51,314104 claims |
| PfizerEliquis | $154 | $46,26359 claims |
| Johnson & JohnsonXarelto | $44 | $30,95228 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $177 | $9,67721 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $5,47112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 medical providers in North Carolina.
Other medical in Rockingham
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$269K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
- John RobbinsWinston Salem$26K
- Ashley TipperStatesville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.